AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01043068
Drug: Cancer pain management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
Trial: NCT02900729
Drug: Amlodipine, losartan potassium and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
Trial: NCT03684616
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous statin treatment for 3 months prior to cardiac arrest
Trial: NCT00775138
Drug: 280 mg Arikayce™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT00775138
Drug: Matching Placebo for Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT00775138
Drug: 560 mg Arikayce™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT03964350
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.
Trial: NCT01156857
Drug: PGL4001, progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
Trial: NCT03327740
Drug: DTG based ARV regimen with ABC
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV regimens containing DTG and ABC
Trial: NCT03327740
Drug: DTG based ARV regimen without ABC
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG based ARV regimens that do not contain ABC
Trial: NCT03327740
Drug: RAL or EGV based ARV regimens with ABC
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL or EGV based regimens containing ABC
Trial: NCT03327740
Drug: RAL or EGV based regimens without ABC
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL or EGV based ARV regimens that do not contain ABC
Trial: NCT03327740
Drug: Any other DTG based ARV regimen as monotherapy
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
Trial: NCT00166504
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin/ezetimibe 10/20 mg
Trial: NCT01419236
Drug: Testosterone Solution 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered topically
Trial: NCT01419236
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered topically
Trial: NCT02209714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04504734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg tablets
Trial: NCT01131507
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
Trial: NCT01964651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally administered once daily for 10 days.
Trial: NCT02831894
Drug: 25% Hypnotic Medication Taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
Trial: NCT02831894
Drug: 10% Hypnotic Medication Taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
Trial: NCT01601093
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
Trial: NCT01601093
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
Trial: NCT02939573
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized to azathioprine 2 mg/kg/day
Trial: NCT02392429
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given anthracycline IV
Trial: NCT02746081
Drug: BAY1436032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
Trial: NCT00848172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical capsules
Trial: NCT04335552
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
Trial: NCT02300922
Drug: Antibody TF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
Trial: NCT02300922
Drug: 90-Y-IMP-288
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
Trial: NCT02300922
Drug: 111-In-IMP-288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
Trial: NCT02249663
Drug: Dymista™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 137/50 mcg Nasal Spray
Trial: NCT00181168
Drug: Euthyroid Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
Trial: NCT01775501
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01775501
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02151864
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
Trial: NCT00520949
Drug: Cebes (colloidal bismuth subcitrate)
RxNorm normalized name: N'ICE Cubes 8 MG Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colloidal bismuth subcitrate 240 mg b.i.d
Trial: NCT00520949
Drug: Esso (esomeprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg b.i.d for 14 days
Trial: NCT00202280
Drug: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04046848
Drug: OCTA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
Trial: NCT04199351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 171 placebo
Trial: NCT02177695
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Trial: NCT02177695
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Trial: NCT04540185
Drug: NA-831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: NA-831 30 mg of NA-831 in a capsule administered orally
Trial: NCT04540185
Drug: Comparable Placebo of drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 mg in a capsule administered orally
Trial: NCT03190174
Drug: Nab-Rapamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
Trial: NCT01173874
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Trial: NCT01520727
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Trial: NCT01520727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose
Trial: NCT00628680
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
Trial: NCT01474993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
Trial: NCT02443688
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02443688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568295
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Trial: NCT00568295
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Trial: NCT00568295
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Trial: NCT01691534
Drug: Rifafour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifafour e-275 mg dosed by weight
Trial: NCT03891706
Drug: tumor-specific TCR-T cells
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
Trial: NCT01416259
Drug: Withdraw treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492999
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00492999
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02870738
Drug: Bladder Instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
Trial: NCT03161015
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01903096
Drug: Primary Care Treatment As Usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
Trial: NCT02117024
Drug: Metronomic Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
Trial: NCT02117024
Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed
Trial: NCT03864783
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®.
Trial: NCT00463814
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of AZD6244 as described in arm description.
Trial: NCT00474123
Drug: Simvastatin 80 mg/day for 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg/day, single dose, for 6 weeks.
Trial: NCT00474123
Drug: Ezetimibe 10 mg / Simvastatin 20 mg
RxNorm normalized name: ezetimibe 10 MG / simvastatin 20 MG [Vytorin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
Trial: NCT01077310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
Trial: NCT00316212
Drug: INS50589 Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00772538
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01779830
Drug: LY2624803 - Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules.
Trial: NCT01779830
Drug: Placebo - Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules.
Trial: NCT01779830
Drug: Placebo - Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablets.
Trial: NCT04484610
Drug: Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain
RxNorm normalized name: Arthricare for Women Pain Relieving Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
Trial: NCT00808132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule, placebo (over-encapsulated), once a day for one year.
Trial: NCT00531466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally three times a day for 28 days
Trial: NCT01229098
Drug: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
Trial: NCT03547908
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
Trial: NCT03547908
Drug: Placebo to match DTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily, without regard to food
Trial: NCT02944110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of placebo tablets
Trial: NCT00914849
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01098435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing lactose and no active drug for daily oral administration
Trial: NCT03346538
Drug: Continuous infusion high-dose MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT03346538
Drug: Continuous infusion placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT03346538
Drug: Approved dosing regimen MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT03346538
Drug: Approved dosing regimen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT00841854
Drug: tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline 500mg qid
Trial: NCT00352027
Drug: Adriamycin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Trial: NCT00352027
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
Trial: NCT01536886
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04269629
Drug: Insect Venom
RxNorm normalized name: insect venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
Trial: NCT03516123
Drug: CS3006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Trial: NCT02872090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03698695
Drug: THN 201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
Trial: NCT03698695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil placebo and Mefloquine placebo
Trial: NCT03700424
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution of 0.90% w/v of sodium chloride (NaCl) in water